Reference priceRUB ₽57,750.00Original source price: INR 52,500.00. Converted estimates are available by currency selection.
| Brand | Nerlynx |
|---|---|
| Manufacturer | Pierre Fabre Pharma GmbH |
| Prescription required | Yes |
Nerlynx 40mg Filmtabletten,180ST x 40mg(Neratinib)
Neratinib
Description
Nerlynx 40mg Filmtabletten,180ST x 40mg(Neratinib) is a medicine catalog record in the MediPriceHub database. Active ingredient: Neratinib. Clinical use summary: See the Benefits field on this page for the product-specific indication or intended use. That field is kept separate from catalog metadata so users can distinguish clinical information from packaging information. Manufacturer or supplier: Pierre Fabre Pharma GmbH. Therapeutic category: Medicine Library > Oncology Medicines > Breast Cancer Drugs. Pack information: 40 / 180. Origin country or market: Germany. This page is for medicine catalog reference only and should be read together with the approved prescribing information in the patient or buyer's country.Benefits
NERLYNX is a kinase inhibitor indicated: As a single agent, for the extended adjuvant treatment of adult patients with early-stage HER2-positive breast cancer, to follow adjuvant trastuzumab-based therapy. In combination with capecitabine, for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 based regimens in the metastatic setting. 1.1 Extended Adjuvant Treatment of Early-Stage Breast Cancer NERLYNX as a single agent is indicated for the extended adjuvant treatment of adult patients with early-stage human epidermal growth factor receptor 2 (HER2)-positive breast cancer, to follow adjuvant trastuzumab based therapy [see Clinical Studies ] . 1.2 Advanced or Metastatic Breast Cancer NERLYNX in combination with capecitabine is indicated for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 based regimens in the metastatic setting [see Clinical Studies ] .How to Use
Use Neratinib under the supervision of a qualified healthcare professional. Take it by mouth only according to the approved label and the dose prescribed by a qualified healthcare professional. Do not start, stop, change the dose, split or crush a dosage form, mix with other medicines, or repeat a course unless the approved product information or a clinician confirms that it is appropriate. Check the local prescribing information for age limits, dose adjustments, missed-dose instructions, storage after opening or reconstitution, and monitoring requirements.Specification
Active ingredient: Neratinib. Pack size: 40 / 180. Pack unit: bottle. Manufacturer: Pierre Fabre Pharma GmbH. Origin country: Germany. Source category: Medicine Library > Oncology Medicines > Breast Cancer Drugs. Availability, prescription status, storage, and exact approved use may vary by country. Check the local product information before clinical or procurement decisions.Side Effects
Cancer medicines may cause fatigue, nausea, vomiting, diarrhea or constipation, appetite changes, mouth sores, rash, changes in blood counts, infection risk, liver or kidney test changes, bleeding risk, neuropathy, infusion reactions, or organ-specific toxicity depending on the medicine. Seek urgent medical care for severe allergic symptoms, breathing difficulty, fainting, severe skin reactions, chest pain, confusion, serious bleeding, signs of infection, or rapidly worsening symptoms. The approved local prescribing information is the controlling source for the complete adverse-reaction profile.Эта информация носит справочный характер. Перед применением лекарства проконсультируйтесь с медицинским специалистом.